• Evaluation of Common Polymorphisms in the BRCA1 Gene in the Iranian Genomic Profile of Breast Cancer by Age and Assessment of Drug Side Effects
  • Majid Mesgar Tehrani,1,* Zahra Gholami,2 Mohammadmahdi Eslami,3 Reza Mirlohi,4
    1. Member of the Core Committee of the National Genomics Hub, Shahid Beheshti University of Medical Sciences, Tehran, Iran
    2. MSc in Midwifery, Independent Researcher, Iran
    3. Member of the Bioinformatics Research Group, Nasim Research Institute, Tehran, Iran
    4. Member of the Bioinformatics Research Group, Nasim Research Institute, Tehran, Iran


  • Introduction: Breast cancer is the most common malignancy among Iranian women, with incidence patterns also dependent on age, and for its treatment, common gene polymorphisms may exhibit distinct drug-related side effects.
  • Methods: Data were retrieved from the NCBI database and analyzed using the pharmacogenomics software MegaGene for polymorphism information analysis and identification of drug-related side effects of genetic origin.
  • Results: For the administration of breast cancer therapeutic drugs, it is essential to perform genetic tests prior to drug prescription and therapy to assess the presence of polymorphisms in common genes, including STK11, MLH1 and DKC1, so that, if polymorphisms are detected, drugs with fewer effects can be prescribed for patients.
  • Conclusion: rs741765, rs63751221 and rs2728726. Are three common polymorphisms in breast cancer. The occurrence of drug side effects is expressed based on individual's genetics.
  • Keywords: Breast cancer, Polymorphisms, BRCA1, Iranian genomic, Genetic test